Innovent Approved to Start US Trials of Novel Immunotherapy
publication date: Dec 5, 2018
Suzhou Innovent Biologics was approved to start US clinical trials of its recombinant fully human anti-OX40 mAb, which Innovent intends to test in patients with solid tumors. IBI101, the third Innovent candidate to start US trials, targets the tumor necrosis factor receptor superfamily member 4. Eventually, the company plans to test IBI101 in combination with other immunotherapies, including its own PD-l candidate. At present, there are no approved OX40 mAbs, but based on pre-clinical data, Innovent believes IBI101 causes a larger T cell response than candidates from other companies. More details....
Stock Symbol: (HK: 01801)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.